Skip to main content
Smart Investors Daily
YM

NASDAQ · YMTX

Yumanity Therapeutics, Inc.

Healthcare · Biotechnology

$1.89

Up+$0.15 (+8.62%)

Updated Sep 10, 2026, 11:10 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
15.72M
P/E ratio
-0.96
Dividend yield
0.00%
52-week range
— – —
Volume
697.48K
Avg. volume
127.73K

Price performance

YMTX price history

1M range · 0 trading sessions · Daily adjusted prices

YMTX does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest YMTX news

The latest Smart Investors Daily articles mentioning YMTX.

YMTX research

Overview

Company profile and research snapshot.

Company profile

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
YMTX recent ratings
DateFirmRatingTarget
Jun 4, 2021HC Wainwright & Co.Buy
Apr 1, 2021JefferiesBuy
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Dec 14, 2022

Dow Surges Over 100 Points; Charter Communications Shares Slide

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Wednesday The Dow traded up 0.42% to 34,252.62 while the NASDAQ rose 0.47% to 11,309.44. The S&P 500 also rose, gaining, 0.47% to 4,038.37. Also check this: Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers Leading and Lagging Sectors Utilities shares rose by 1.1% on Wednesday. Meanwhile, top gainers in the sector included Genie Energy Ltd. (NYSE: GNE), up 5%, and Cadiz Inc. (NASDAQ: CDZI), up 9%. In trading on Wednesday, energy shares fell by 1%. Top Headline   US import prices fell 0.6% from a month ago in November versus a revised 0.4% drop in the prior month. Export prices declined by 0.3% from a month earlier.   Equities Trading UP   Avidity Biosciences, Inc. (NASDAQ: RNA) shares shot up 75% to $19.19 after the company announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever successful targeted delivery of RNA into muscle. Shares of Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) got a boost, shooting 88% to $0.4724 after the company entered into a definitive merger agreement with GRI Bio. Immix Biopharma, Inc. (NASDAQ: IMMX) shares were also up, ...

Benzinga · Dec 14, 2022

US Stocks Higher Ahead Of Fed Decision

U.S. stocks traded higher this morning, with the Dow Jones gaining over 80 points on Wednesday Following the market opening Wednesday, the Dow traded up 0.24% to 34,191.95 while the NASDAQ rose 0.13% to 11,271.20. The S&P 500 also rose, gaining, 0.21% to 4,027.98. Also check this: Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers Leading and Lagging Sectors Utilities shares rose by 0.8% on Wednesday. Meanwhile, top gainers in the sector included Sunnova Energy International Inc. (NYSE: NOVA), up 4%, and Cadiz Inc. (NASDAQ: CDZI), up 9%. In trading on Wednesday, materials shares fell by 0.3%. Top Headline   US import prices fell 0.6% from a month ago in November versus a revised 0.4% drop in the prior month. Export prices declined by 0.3% from a month earlier.   Equities Trading UP   Avidity Biosciences, Inc. (NASDAQ: RNA) shares shot up 38% to $15.13 after the company announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever successful targeted delivery of RNA into muscle. Shares of BIMI International Medical, Inc. (NASDAQ: BIMI) got a boost, shooting 32% to $2.74. BIMI reported entry into a material definitive agreement for the acquisition of Wuzhou Qiangsheng Hospital Co., Ltd., Suzhou Eurasia Hospital Co., ...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.